Recent news on Natalizumab

Withdrawn MS drug returns to market  -  25 May 2007
SpiritIndia,Just months after receiving FDA approval, natalizumab, a medication for the treatment of multiple sclerosis (MS) and other inflammatory disorders,

Data Presented At The American Academy Of Neurology's Annual ...  -  May 8, 2007
Medical News Today (press release),...data from the TOUCH Prescribing Programä and TYGRIS safety study confirm the safety profile from previous clinical studies of TYSABRI® (natalizumab).

Biogen Idec Reports First Quarter 2007 Results  -  May 2, 2007
PharmaLive.com (press release),Global in-market net sales of TYSABRI(R) (natalizumab) in the first quarter of 2007 were $48 million. Based on our collaboration structure with Elan,

Tysabri 'cost effective' for public use  -  Apr 27, 2007
Unison.ie (subscription),The study concluded that: "Reimbursement may be considered on the basis that natalizumab (Tysabri) appears cost effective from the societal perspective and

Natalizumab (Tysabri) reduces vision loss in MS patients  -  Apr 18, 2007
News-Medical.net,..."Not only does natalizumab prevent the worsening of vision loss in people with relapsing MS, but it is also associated with significant reductions in the

Natalizumab (Tysabri) Reduces Vision Loss in MS  -  Apr 17, 2007
MedPage Today,Note that these industry-sponsored studies suggests that the monoclonal antibody natalizumab (Tysabri) reduces the risk of clinically significant vision

Natalizumab helps reduce vision loss  -  Apr 18, 2007
News-Medical.net,More than half of the people received the drug natalizumab every four weeks for two years. The rest of the group received placebo.

Treatment For MS Patients Also Reduces Their Vision Loss, Penn ...  -  Apr 20, 2007
Medical News Today (press release),According to a study that appears in Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI®) - a

Drug reduces vision loss associated with relapsing multiple ...  -  Apr 17, 2007
OSN SuperSite (subscription),Natalizumab, a drug that slows disability and reduces relapse rates in patients with multiple sclerosis, may also reduce vision loss associated with the

MS drug fights vision loss  -  Apr 18, 2007
Health24.com,..."For patients who are on natalizumab or considering natalizumab, this gives them another piece of information to consider as they are trying to make their

Tysabri reduces vision loss in recurring multiple sclerosis  -  Apr 18, 2007
Earthtimes.orgThe drug called natalizumab (brand name Tysabri) is commonly used in MS patients to reduce disability and to also slow down possible relapse.

Tysabri - new option for multiple sclerosis  -  Apr 2, 2007
Healthcare RepublicBiogen Idec has launched Tysabri (natalizumab) as single disease modifying therapy in highly active relapsing-remitting multiple sclerosis for patients with

Ireland's Elan still smiling despite increase in losses  -  Apr 25, 2007
Pharma Times (subscription),13% to $59.4 million, but most interest was on the performance of Tysabri (natalizumab), partnered with Biogen Idec, which had sales of $48.4 million.

MS Patients Not Receiving Medications To Slow Disease Progression ...  -  Apr 20, 2007
Medical News Today (press release),...interferon-1a (Avonex®), glatiramer acetate (GA or Copaxone®), interferon-1a (Rebif®), mitoxantrone (Novantrone®) and natalizumab (Tysabri®).

MS patients not receiving medications to slow disease progression  -  Apr 18, 2007
News-Medical.net,...interferon-1a (Avonex), glatiramer acetate (GA or Copaxone), interferon-1a (Rebif), mitoxantrone (Novantrone) and natalizumab (Tysabri).

Multiple Sclerosis Drug Combats Vision Loss  -  Apr 17, 2007
HealthCentral.com,More than half the patients received Tysabri (generic name natalizumab) every four weeks for two years. To evaluate eyesight, the researchers used a

Biogen has high hopes for Tysabri's future as earnings soar  -  Feb 16, 2007
Pharma Times (subscription),Global sales of new MS drug Tysabri (natalizumab), which is partnered with Elan and only returned to the market in July after being pulled off on safety

Tysabri forecast to drive Elan's return to profitability  -  Feb 21, 2007
Pharma Times (subscription),However all eyes were on Tysabri (natalizumab), partnered with Biogen Idec, which had sales of $30.2 million. The drug only returned to the market in July

Biogen Idec Reports Full Year and Fourth Quarter 2006 Results  -  Feb 15, 2007
WebWire (press release),During 2006, Biogen Idec also successfully launched RITUXAN in rheumatoid arthritis (RA) and TYSABRI® (natalizumab) in multiple sclerosis (MS).

Elan And Biogen Idec Submit Supplemental Biologics License ...  -  Jan 2, 2007
Medical News Today (press release),...multi-center trials of TYSABRI assessing the safety and efficacy as both an induction and maintenance therapy - ENCORE (Efficacy of Natalizumab in

Conversation with…Dr. Jeffrey Hyams Top pediatric GI sees research ...  -  Jan 16, 2007
Connecticut Jewish Ledger,...the primary investigator for the two largest pediatric clinical trials of new medications involving Remicade (infliximab) and Tysabri (natalizumab).

I've been told that I have MS. What course will it take?  -  Dec 21, 2006
Times Online,A new drug Tysabri, (natalizumab), has been introduced recently. It is being used carefully and has not yet been approved by the National Institute for

Current and Emerging Strategies in Biologic Therapy for IBD  -  Dec 4, 2006
Medscape (subscription)...in patients on combined immunosuppressant therapy (namely, progressive multifocal leukoencephalopathy [PML] associated with natalizumab and hepatosplenic T ...

Elan and Biogen Idec Submit Supplemental Biologics License ...  -  Dec 15, 2006
Business Wire (press release),...of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) seeking approval to market TYSABRI® (natalizumab) in the ...

Market Report -- In Play (ELN)  -  Dec 15, 2006
MSN Money...multi-center trials of TYSABRI assessing the safety and efficacy as both an induction and maintenance therapy - ENCORE (Efficacy of Natalizumab in Crohn's ...

Clinical Trials Update: Dec. 19, 2006  -  Dec 19, 2006
Forbes,This study will evaluate an investigational use of a medication called natalizumab to treat multiple sclerosis. Volunteers 18-55 ...

Clinical Trial Design  -  Nov 27, 2006
Medscape (subscription)The Safety and Efficacy of Natalizumab in Combination with Avonex (interferon beta-1a) (SENTINEL) trial is an example of add-on therapy because natalizumab was ...

I've been told that I have MS. What course will it take?  -  Dec 21, 2006
Times Online,Both reduce the severity of the relapses and their frequency. A new drug Tysabri, (natalizumab), has been introduced recently. It ...

Genentech and Biogen Idec disclose Rituxan-related deaths  -  Dec 19, 2006
Pharma Times (subscription),Although rare, PML has been in the news recently and it was the reason why Biogen and Elan's Tysabri (natalizumab) was voluntarily pulled from sale in 2005 ...

Tysabri treatment to Scots with multiple sclerosis (MS)  -  Dec 13, 2006
SpiritIndia,...is dismayed by the SMC decision to deny this treatment to around 1,000 Scots living with rapidly deteriorating MS, by banning the drug Tysabri (natalizumab). ...

Elan and Biogen file Tysabri for Crohn's  -  Dec 18, 2006
Pharma Times (subscription),...to the US Food and Drug Administration is based on the findings of three Phase III trials assessing the safety and efficacy of Tysabri (natalizumab) as both an ...

2006 - A Very Good Year In MS Research  -  Dec 8, 2006
Medical News Today (press release),The FDA approved the return to market of Tysabri(R) (natalizumab, produced by Biogen Idec and Elan Pharmaceuticals) to delay the accumulation of physical ...

2006 - A Very Good Year in MS Research  -  Dec 7, 2006
Yahoo! News (press release)The FDA approved the return to market of Tysabri® (natalizumab, produced by Biogen Idec and Elan Pharmaceuticals) to delay the accumulation of physical ...

Natalizumab Induces Sustained Response and Remission in Patients ...  Oct 27, 2006
BERLIN, GERMANY -- October 27, 2006 -- Natalizumab is well tolerated and provides significant benefits in the induction of sustained response and remission in ... -DG News Natalizumab Maintains Remission for 2 Years in Patients With ...  Oct 30, 2006
BERLIN, GERMANY -- October 30, 2006 -- Remission induced by natalizumab can be maintained by continuous therapy for periods more than 2 years in patients with ... -DG News Natalizumab Shows Potential in Treating Moderate-to-Severe Crohn's ...  Oct 30, 2006
LAS VEGAS, NV -- October 30, 2006 -- Natalizumab (Tysabri), a biologic agent approved for treatment of multiple sclerosis, may also have a role in the ... -DG News International Approvals: Sebivo and Tysabri  Oct 23, 2006
B virus infection in compensated patients with evidence of viral replication and active liver inflammation; Health Canada has approved natalizumab injection as ... -Medscape (subscription) Transition Therapeutics Announces First Quarter Fiscal 2007 ...  Nov 6, 2006
MS-IET for MS The landscape of the MS therapeutic market has changed significantly with the re-introduction of natalizumab (Tysabri(R)) and the promising data ... -Canada NewsWire (press release), Biogen Idec Reports Third Quarter 2006 Results  Oct 31, 2006
TYSABRI(R) (natalizumab) has been launched in the US and Europe for the treatment of relapsing forms of multiple sclerosis (MS) following regulatory ... -Genetic Engineering News (press release), Amylin Pharmaceuticals Expands Clinical Program in Obesity and ...  Oct 25, 2006
Elan Corporation, plc (NYSE:ELN) and Biogen Idec (NASDAQ:BIIB) announced recently data that show TYSABRI® (natalizumab) maintained remission in Crohn's ... -Financial News USA (press release), Biogen Idec Reports Third Quarter 2006 Results  Oct 31, 2006
Biogen Idec’s third quarter 2006 non-GAAP diluted earnings per share (EPS) was $0.60, up 67% from the same period last year. * TYSABRI® (natalizumab) has ... -WebWire (press release), Elan and Biogen Idec announce positive test results for Tysabri in ...  Oct 24, 2006
Irish drugs firm Elan Corporation and US biotech company Biogen Idec announced today data that show Tysabri (natalizumab) maintained remission in Crohn's ... -FinFacts Ireland, Market Report -- In Play (ELN)  Oct 24, 2006
Crohn's Disease treated for longer than 2 yrs, according to data Co and Biogen (BIIB) announced today data that show TYSABRI (natalizumab) maintained remission ... -MSN Money Tysabri Maintained Remission in Patients with Moderate-to-Severe ...  Oct 24, 2006
Oct 24, 2006 - Elan Corporation, plc (NYSE:ELN) and Biogen Idec (NASDAQ:BIIB) announced today data that show TYSABRI(R) (natalizumab) maintained remission in ... -PharmaLive.com (press release), TYSABRI ® Maintained Remission in Patients with Moderate-to ...  Oct 24, 2006
BUSINESS WIRE)--Elan Corporation, plc (NYSE:ELN) and Biogen Idec (NASDAQ:BIIB) announced today data that show TYSABRI ® (natalizumab) maintained remission in ... -Business Wire (press release), Genzyme Extends AnorMed Buyout Offer and Medicis to Host ...  Oct 9, 2006
...of Managed Care Pharmacy's (AMCP) 2006 Educational Conference in Chicago, IL show that in Phase III studies TYSABRI® (natalizumab) therapy significantly ... -Financial News USA (press release), Natalizumab Has Benefits on Disability and Quality of Life in ...  Sep 11, 2006
GLASGOW, UK -- September 11, 2006 -- Monotherapy with the alpha4 integrin antagonist natalizumab results in significant improvements in scores on health ... -DG News

Biogen Joins With Alnylam On RNAi Therapies For PML.  Sep 23, 2006
Elan Corp. plc voluntarily pulled Tysabri (natalizumab) from the market following two patient deaths from PML; however, the ... -Therapeutics Daily (subscription)

Drug for MS Reduces Lesions and Extends Time to Relapse  Sep 13, 2006
...importance of T-cell migration in patients with multiple sclerosis has been impressively demonstrated by the therapeutic effects of natalizumab [Tysabri], a ... -MedPage Today

New Drug Reduces MS Symptoms  Sep 13, 2006
...for this disease. The most recently approved drug for MS treatment, available by infusion, is Tysabri (natalizumab). The drug was ... -Forbes

Tysabri's use for MS limited for now  Sep 12, 2006
Tysabri (brand name for natalizumab) will not make a big difference for most MS patients - at least, not right away - because the FDA reapproval carries a ... -Newsday

DOH:Further Action Taken To Tackle Obesity As Minister Announces ...  Aug 31, 2006
Certolizumab pegol (Certolizumab pegol (Celltech Pharmaceuticals Ltd) and Natalizumab (Antegren, Elan Pharmaceuticals & Biogen Idec) are new drugs for the ... -Medical News Today

STANFORD DOCTORS SPOTLIGHT FATAL FLAW IN MULTIPLE SCLEROSIS DRUG ...  Sep 5, 2006
...would do fine without the drug. The drug in question is natalizumab, which has the brand name of Tysabri. In November 2004, the US ... -Newstarget.com

Stem cell treatment is worth the risks  Aug 30, 2006
Natalizumab, marketed as Tysabri, was licensed for use throughout the EU in June after clinical trials found it slowed the progression of the disease and ... -The Northern Echo

TYSABRI NOW BEING ADMINISTERED AT MULTIPLE SCLEROSIS CENTER OF ...  Sep 7, 2006
ATLANTA – The Multiple Sclerosis Center of Atlanta (MSCA) has announced it is now administering TYSABRI® (natalizumab), the drug recently re-released by the ... -dBusinessNews Atlanta

NICE Welcomes Referral Of New Work Programme Topics, UK  Aug 31, 2006
CAT-152) for glaucoma; carmustine implants (Gliadel Wafers) for glioma (recurrent); nesiritide (Natrecor) for acute heart failure; natalizumab (Tysabri) for ... -Medical News Today

New MS drug on licensing fast track  Aug 31, 2006
The National Institute for Health and Clinical Excellence (Nice) is assessing Natalizumab, marketed as Tysabri, under its faster Single Technology Assessment ... -Therapeutics Daily (subscription)

Current and Emerging Strategies in Biologic Therapy for IBD  -  Dec 4, 2006
Medscape (subscription)Natalizumab* is a recombinant, humanized IgG4 monoclonal antibody against alpha 4 integrin that blocks alpha 4 beta 1 and alpha 4 beta 7 , thus preventing

2006 - A Very Good Year In MS Research  -  Dec 8, 2006
Medical News Today (press release),The FDA approved the return to market of Tysabri(R) (natalizumab, produced by Biogen Idec and Elan Pharmaceuticals) to delay the accumulation of physical

Clinical Trial Design  -  Nov 27, 2006
Medscape (subscription)The Safety and Efficacy of Natalizumab in Combination with Avonex (interferon beta-1a) (SENTINEL) trial is an example of add-on therapy because natalizumab

Multiple sclerosis: Natalizumab's potentially deadly side effect ...  Aug 15, 2006
Researchers have completed an extensive study of more than 3,000 patients who received a Natalizumab ( Tysabri ), that was linked to three cases of a serious ... -Xagena.it

Concern Over Fast Tracking of New Drugs  Aug 21, 2006
It follows approval of natalizumab, a new drug for multiple sclerosis, and its recall three months later, after three trial patients developed a life ... -Newstarget.com

Coram, Inc. Infusion Suites Now Providing Tysabri Infusions  Aug 23, 2006
...home infusion and specialty pharmaceutical distribution services, has announced that it has been approved to provide Tysabri(r) (natalizumab), the monotherapy ... -PrimeZone

Tysabri back on market  Aug 2, 2006
The return of the multiple sclerosis (MS) drug Tysabri (natalizumab) to the US market, sanctioned by the US Food and Drug Administration (FDA) on June 5, and ... -Nature.com (subscription)

Elan Reports Second Quarter 2006 Financial Results  Jul 31, 2006
The results from the Phase 3 ENCORE (Efficacy of Natalizumab in Crohn's Disease Response and Remission) trial in Crohn's disease were presented at Digestive ... -Business Wire

Elan says losses narrow in Q2  Aug 1, 2006
Tysabri (natalizumab) has now been returned to the market in Germany, Ireland, the UK, Sweden and the USA, having been withdrawn last year over links to a rare ... -Pharma Times (subscription)

Biogen Idec Reports Second Quarter 2006 Results  Jul 26, 2006
TYSABRI(R) (natalizumab) has been approved for reintroduction by the US Food and Drug Administration (FDA), and for marketing by the European Commission, as ... -Finanzen.net

Elan/Biogen Idec: Tysabri back on the shelves  Jul 26, 2006
...'Content Following the recent approvals by both US and European regulators, Biogen Idec and Elan have re-launched Tysabri (natalizumab) in the US and ... -Pharmaceutical Business Review

Biogen Idec Slips To Loss In Q2 On Charges, Adj. EPS Rises 33% ...  Jul 26, 2006
...plc revealed the commercial availability of Tysabri or natalizumab for the treatment of relapsing forms of multiple sclerosis in the US. ... -Trading Markets

Tysabri (Natalizumab) Receives Approval in European Union for ...  Jun 29, 2006
2006 -- Biogen Idec and Elan Corporation, plc today announced that they received approval from the European Commission to market Tysabri® (natalizumab) as a ... -DG News

Companies Release New Drug for MS  Jul 20, 2006
...sclerosis (MS). Biogen Idec and Elan Pharmaceuticals announced they'll be marketing a drug called Tysabri® (natalizumab). The FDA ... -WOAI

International Approvals: Preotact, Tysabri, Relenza  Jul 10, 2006
...hormone once-daily subcutaneous injection for the treatment of postmenopausal osteoporosis in women at high risk for fractures and natalizumab monotherapy to ... -Medscape (subscription)

Spotlight on Multiple Sclerosis  Jun 23, 2006
...themselves. Natalizumab (Tysabri®) has just been approved for re-release by the FDA for treatment of relapsing-remitting MS. This ... -FOX News

Archemix Signs Aptamer Deal With Elan For Up To $350M  Jul 13, 2006
...in the disease area; it has a product pipeline aimed at multiple sclerosis and Crohn's disease, including the MS drug, Tysabri (natalizumab), marketed with ... -BioWorld Online

TYSABRI (R) Receives Approval in European Union for the Treatment ...  Jun 29, 2006
Today announced that they received approval from the European Commission to market TYSABRI(R) (natalizumab) as a treatment for relapsing remitting multiple ... -PipelineReview.com

TYSABRI(R) Receives Approval in European Union for the Treatment ...  Jun 28, 2006
BIIB) and Elan Corporation, plc(NYSE: ELN) today announced that they received approval from theEuropean Commission to market TYSABRI(R) (natalizumab) as a ... -Finanzen.net

European Commission gives approval to Elan's Tysabri MS drug  Jun 29, 2006
Idec and Irish drugs firm Elan Corporation, plc today announced that they received approval from the European Commission to market TYSABRI (natalizumab) as a ... -FinFacts Ireland

Biogen Idec/Elan: a new market for Tysabri  Jun 29, 2006
...'Content Tysabri (natalizumab) was voluntarily withdrawn from the US multiple sclerosis (MS) market in February 2005, after one patient died from progressive ... -Pharmaceutical Business Review

Biotech on a Downward Slide in Q2 06  Jul 3, 2006
...the fact that Biogen Idec and Elan Corporation, plc reported that they had received approval from the European Commission to market Tysabri (natalizumab) as a ... -International News Service

Tysabri gets EC approval for relapsing MS  Jul 3, 2006
Biogen Idec and Ireland's Elan say that the European Commission has granted marketing approval for the co-developed multiple sclerosis drug Tysabri (natalizumab ... -Therapeutics Daily (subscription)



CHMP Issues Positive Opinion for Tysabri (Natalizumab) as a ...  Apr 28, 2006
...scientific committee of the European Medicines Agency (EMEA), issued a positive opinion recommending marketing authorization for Tysabri® (natalizumab) as a ... - DG News

Biogen and Elan's Tysabri gets positive EU opinion  May 2, 2006
The positive opinion is for Tysabri (natalizumab) as a treatment for relapsing-remitting multiple sclerosis (MS) to delay the progression of disability and ... - Pharmaceutical Business Review

Multiple Sclerosis Research  May 3, 2006
Researchers are studying medications such as Rolipram, Zenapax, Natalizumab, and Novantrone for treating multiple sclerosis, and non-medicine treatments such ... - About - News & Issues

American Academy of Neurology 58th Annual Meeting Scientific ...  Apr 18, 2006
Another study showed that natalizumab delays disease progression, reduces disability progression, and reduces brain lesions. Natalizumab ... - Newswise

FDA's Likely Approval to Relaunch Tysabri, Despite Rare Fatal Side ...  May 2, 2006
...and advisory firms focusing on pharmaceutical and health care issues, finds that the likely reintroduction of Biogen Idec/Elan's Tysabri (natalizumab) in the ... - Drug Newswire

Biogen Idec buys cancer drug firm Conforma  May 4, 2006
...to invest hard cash to grow its pipeline and plug a gap caused by last year's suspension from sale of multiple sclerosis drug Tysabri (natalizumab), as well as ... - Pharma Times (subscription)

Biogen Idec Reports First Quarter 2006 Results  Apr 26, 2006
...the Peripheral and Central Nervous System Drugs Advisory Committee of the FDA voted unanimously to recommend reintroduction of TYSABRI(R) (natalizumab) as a ... - Genetic Engineering News

PharmaFrontiers Gets $23M To Advance MS Compound  Apr 17, 2006
A broader approach for MS could mean trouble. Witness Tysabri (natalizumab), the compound from Cambridge, Mass.-based Biogen Idec Inc. and Elan Corp. ... - BioWorld Online (subscription)

CHMP positief over TYSABRI als behandeling van relapsing-remitting ...  Apr 28, 2006
...scientific committee of the European Medicines Agency (EMEA), issued a positive opinion recommending marketing authorization for TYSABRI(R) (natalizumab) as a ... - Netherlands Corporate News (persbericht)

CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for ...  Apr 28, 2006
...scientific committee of the EuropeanMedicines Agency (EMEA), issued a positive opinion recommendingmarketing authorization for TYSABRI(R) (natalizumab) as a ... - Finanzen.net

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional